Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 3/20 | 0.40 |
| ▸ | FNTB | P49356 | 3/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4837685 | 0.91 | TAAR1 (0.47) | TAAR1FNTAFNTBPGGT1BHRH3 | |
| Trifluoroacetic Acid SCHEMBL4846619 | 0.85 | MMP2 (0.35) | HPSE | |
| Trifluoroacetic Acid SCHEMBL4834343 | 0.84 | MAP3K8 (0.35) | HPSE | |
| Trifluoroacetic Acid SCHEMBL4841466 | 0.84 | NPC1 (0.35) | HPSE | |
| Trifluoroacetic Acid SCHEMBL4838725 | 0.84 | MMP2 (0.34) | HPSE | |
| Trifluoroacetic Acid SCHEMBL4841657 | 0.84 | TAAR1 (0.41) | TAAR1FNTAFNTBPGGT1BHPSE | |
| Trifluoroacetic Acid SCHEMBL5259763 | 0.83 | MMP2 (0.35) | HPSE | |
| Trifluoroacetic Acid SCHEMBL4845670 | 0.83 | FFAR1 (0.42) | HPSE | |
| Trifluoroacetic Acid SCHEMBL4844134 | 0.82 | HPSE (0.36) | HPSE | |
| Trifluoroacetic Acid SCHEMBL4840394 | 0.81 | SYK (0.35) | HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410966-B2 | Use of and some novel imidazopyridines | ASTRAZENECA AB (SE) | 2008-08-12 | — | — | US | disclosed |
| EP-1539759-B1 | NOVEL IMIDAZOPYRIDINES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-08-15 | — | — | EP | disclosed |
| US-20050261333-A1 | Use of and some novel imidazopyridines | ASTRAZENECA A B (SE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261333-A1 | Use of and some novel imidazopyridines | ITK, CSNK1A1, RPS6KA1 | TAAR1 2145/4885FNTA 4054/4885FNTB 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.